BioCentury
ARTICLE | Clinical News

One year data for Cor's Integrilin

May 23, 2001 7:00 AM UTC

One year follow-up analysis of 98.1% of 2,064 patients undergoing coronary artery stenting from the ESPRIT Phase IV study of CORR's Integrilin eptifibatide showed that the benefit conferred by Integri...